|112.75||+4.11||+3.78%||Vol 1.11M||1Y Perf -19.45%|
|Oct 2nd, 2023 16:00 DELAYED|
|- -||2.25 2.00%|
|Target Price||217.60||Analyst Rating||Moderate Buy 2.09|
|Potential %||92.99||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★★ 66.21|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★★ 88.48|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||★★★★+ 59.66|
|Price Range Ratio 52W %||18.45||Earnings Rating||—|
|Market Cap||27.17B||Earnings Date||6th Nov 2023|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th Nov 2023|
|Estimated EPS Next Report||0.92|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||592.47K|
|Avg. Monthly Volume||546.17K|
|Avg. Quarterly Volume||671.92K|
BioNTech SE (NASDAQ: BNTX) stock closed at 112.75 per share at the end of the most recent trading day (a 3.78% change compared to the prior day closing price) with a volume of 1.11M shares and market capitalization of 27.17B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1310 people. BioNTech SE CEO is Ugur Sahin.
The one-year performance of BioNTech SE stock is -19.45%, while year-to-date (YTD) performance is -24.94%. BNTX stock has a five-year performance of %. Its 52-week range is between 95.5 and 188.985, which gives BNTX stock a 52-week price range ratio of 18.45%
BioNTech SE currently has a PE ratio of 3.70, a price-to-book (PB) ratio of 1.89, a price-to-sale (PS) ratio of 2.83, a price to cashflow ratio of 3.00, a PEG ratio of -, a ROA of 52.31%, a ROC of 74.73% and a ROE of 72.05%. The company’s profit margin is 54.91%, its EBITDA margin is 78.80%, and its revenue ttm is $12.77 Billion , which makes it $52.64 revenue per share.
Of the last four earnings reports from BioNTech SE, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.92 for the next earnings report. BioNTech SE’s next earnings report date is 06th Nov 2023.
The consensus rating of Wall Street analysts for BioNTech SE is Moderate Buy (2.09), with a target price of $217.6, which is +92.99% compared to the current price. The earnings rating for BioNTech SE stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioNTech SE has a dividend yield of 1.03% with a dividend per share of $1.53 and a payout ratio of -%.
BioNTech SE has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.03, ATR14 : 3.55, CCI20 : -1.39, Chaikin Money Flow : -0.07, MACD : -2.26, Money Flow Index : 32.30, ROC : -0.93, RSI : 53.79, STOCH (14,3) : 69.50, STOCH RSI : 1.00, UO : 56.15, Williams %R : -30.50), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioNTech SE in the last 12-months were:
Thu, 28 Sep 2023 16:26 GMT Pfizer, BioNTech announce Canada authorization of monovalent vaccine- TipRanks. All rights reserved.
Mon, 11 Sep 2023 17:52 GMT Pfizer, BioNTech announce FDA approval for 2023-2024 COVID-19 vaccine- TipRanks. All rights reserved.
Wed, 30 Aug 2023 14:04 GMT Pfizer, BioNTech report positive CHMP opinion for Omicron XBB.1.5 vaccine- TipRanks. All rights reserved.
Tue, 08 Aug 2023 00:25 GMT BioNTech SE (BNTX) Receives a Hold from Goldman Sachs- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.